Class information for:
Level 1: PULMONARY ARTERIAL HYPERTENSION//TREPROSTINIL//PULMONARY HYPERTENSION

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
876 2907 37.3 83%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
772 11635 PULMONARY HYPERTENSION//PULMONARY ARTERIAL HYPERTENSION//CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PULMONARY ARTERIAL HYPERTENSION Author keyword 347 42% 22% 647
2 TREPROSTINIL Author keyword 96 76% 2% 67
3 PULMONARY HYPERTENSION Author keyword 95 12% 26% 754
4 EPOPROSTENOL Author keyword 72 48% 4% 109
5 BOSENTAN Author keyword 62 30% 6% 174
6 EISENMENGER SYNDROME Author keyword 57 55% 2% 71
7 AMBRISENTAN Author keyword 39 63% 1% 40
8 ENDOTHELIN RECEPTOR ANTAGONISTS Author keyword 35 39% 2% 72
9 PULM HYPERTENS Address 31 35% 2% 72
10 SITAXSENTAN Author keyword 23 69% 1% 20

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PULMONARY ARTERIAL HYPERTENSION 347 42% 22% 647 Search PULMONARY+ARTERIAL+HYPERTENSION Search PULMONARY+ARTERIAL+HYPERTENSION
2 TREPROSTINIL 96 76% 2% 67 Search TREPROSTINIL Search TREPROSTINIL
3 PULMONARY HYPERTENSION 95 12% 26% 754 Search PULMONARY+HYPERTENSION Search PULMONARY+HYPERTENSION
4 EPOPROSTENOL 72 48% 4% 109 Search EPOPROSTENOL Search EPOPROSTENOL
5 BOSENTAN 62 30% 6% 174 Search BOSENTAN Search BOSENTAN
6 EISENMENGER SYNDROME 57 55% 2% 71 Search EISENMENGER+SYNDROME Search EISENMENGER+SYNDROME
7 AMBRISENTAN 39 63% 1% 40 Search AMBRISENTAN Search AMBRISENTAN
8 ENDOTHELIN RECEPTOR ANTAGONISTS 35 39% 2% 72 Search ENDOTHELIN+RECEPTOR+ANTAGONISTS Search ENDOTHELIN+RECEPTOR+ANTAGONISTS
9 SITAXSENTAN 23 69% 1% 20 Search SITAXSENTAN Search SITAXSENTAN
10 PRIMARY PULMONARY HYPERTENSION 23 30% 2% 66 Search PRIMARY+PULMONARY+HYPERTENSION Search PRIMARY+PULMONARY+HYPERTENSION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CONTINUOUS INTRAVENOUS EPOPROSTENOL 479 83% 9% 273
2 INHALED ILOPROST 245 68% 7% 217
3 1ST LINE BOSENTAN 206 98% 2% 52
4 BOSENTAN 156 40% 11% 310
5 BOSENTAN THERAPY 139 66% 4% 128
6 EPOPROSTENOL 121 51% 6% 171
7 SUBCUTANEOUS TREPROSTINIL 106 95% 1% 36
8 PROSTACYCLIN ANALOG 103 46% 6% 170
9 TREPROSTINIL 100 73% 3% 77
10 SITAXSENTAN 93 78% 2% 61

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Guidelines for the diagnosis and treatment of pulmonary hypertension 2009 1122 232 55%
Pulmonary Arterial Hypertension: A Review in Pharmacotherapy 2015 3 47 94%
Definitions and Diagnosis of Pulmonary Hypertension 2013 121 48 69%
Updated Treatment Algorithm of Pulmonary Arterial Hypertension 2013 82 76 87%
Guidelines for the diagnosis and treatment of pulmonary hypertension 2009 465 232 55%
Updated Clinical Classification of Pulmonary Hypertension 2013 202 52 23%
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension 2014 13 83 80%
Drug therapy: Treatment of pulmonary arterial hypertension 2004 771 83 71%
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association 2009 480 208 45%
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association 2009 371 210 45%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PULM HYPERTENS 31 35% 2.5% 72
2 PULM VASC DIS 22 49% 1.1% 32
3 U999 20 38% 1.4% 41
4 REFERENCE HYPERTENS PULM SEVERE 18 45% 1.0% 30
5 MALAD VASC PULM 15 62% 0.6% 16
6 PULM HYPERTENS UNIT 14 57% 0.6% 16
7 MED KLIN 2 5 13 80% 0.3% 8
8 PULM HYPERTENS PROGRAM 12 36% 0.9% 27
9 PULM VASC DIS UNIT 10 37% 0.8% 23
10 PULM VASC DIS PROGRAM 10 48% 0.5% 15

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000213470 PULMONARY VENO OCCLUSIVE DISEASE//PULMONARY CAPILLARY HEMANGIOMATOSIS//PULMONARY CAPILLARY HAEMANGIOMATOSIS
2 0.0000203771 MONOCROTALINE//PULMONARY ARTERIAL HYPERTENSION//BMPR2
3 0.0000198871 CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION//PULMONARY ENDARTERECTOMY//PULMONARY THROMBOENDARTERECTOMY
4 0.0000155792 P DIS P INTENS CARE//SERV MALAD P REANIMAT P//BIOSTAT UNIT MED
5 0.0000148864 RIGHT VENTRICLE//RIGHT VENTRICULAR FUNCTION//TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION
6 0.0000144368 HYPERTHYROIDISM COMPLICATIONS//MEDPULM CRIT CARE SECT//OVERT HYPERTHYROIDISM
7 0.0000125759 SCLERODERMA HEART DISEASE//HEART INVOLVEMENT//SMALL CORONARY ARTERY DISEASE
8 0.0000106714 INHALED NITRIC OXIDE//NITRIC OXIDE INHALATION//GASES NON ANAESTHETIC NITRIC OXIDE
9 0.0000087010 INCREASED PULMONARY BLOOD FLOW//MICROATELECTASIS//AGED 85 AND OVER
10 0.0000085499 HEPATOPULMONARY SYNDROME//PORTOPULMONARY HYPERTENSION//PORTO PULMONARY HYPERTENSION